Data completeness
0/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLAINE (hexylcaine hydrochloride) is a topical local anesthetic solution in pre-launch development by Merck & Co. Specific indications and mechanism of action are not yet publicly detailed, but hexylcaine is a local anesthetic typically used for surface anesthesia. The product represents an early-stage candidate in Merck's topical anesthetic portfolio.
Pre-Launch
Pre-launch stage suggests small, focused development team with growth potential post-approval; commercial infrastructure build-out underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYCLAINE represents a pre-launch opportunity to build commercial and regulatory infrastructure from the ground up within Merck's dermatology or procedural anesthesia franchise. Roles on this team will focus on regulatory approval strategy, clinical evidence synthesis, and commercial launch planning with limited near-term revenue visibility.
Regulatory Affairs Specialist
Worked on CYCLAINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.